Article Details

Uniqure's safety scare shakes haemophilia gene therapy

Retrieved on: 2020-12-21 15:47:26

Tags for this article:

Click the tags to see associated articles and topics

Uniqure's safety scare shakes haemophilia gene therapy. View article details on hiswai:

Excerpt

The group's competitors in haemophilia B include Roche, whose fidanacogene elaparvovec, gained through the acquisition of Spark, is partnered with ...

Article found on: www.evaluate.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up